BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 6970515)

  • 1. Study of lymphocyte subpopulations in patients with systemic lupus erythematosus. In vitro effect of levamisole on T-lymphocyte population.
    Pozsonyi T; Jakab L; Fehér J
    Allergol Immunopathol (Madr); 1980; 8(5):553-8. PubMed ID: 6970515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vitro effect of levamisole on histamine inhibited E-rosette forming T-lymphocyte subpopulation in patients affected by disseminated erythematosus lupus.
    Pozsonyi T; Jakab L; Fehér J; Cseh K
    Allergol Immunopathol (Madr); 1982; 10(6):435-9. PubMed ID: 6220589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The in vitro effect of thymic humoral factor and levamisole on peripheral blood lymphocytes in systemic lupus erythematosus patients.
    Michalevicz R; Many A; Ramot B; Trainin N
    Clin Exp Immunol; 1978 Jan; 31(1):111-5. PubMed ID: 639342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte populations in chronic active liver disease: in vitro effect of levamisole on T-lymphocyte populations.
    Pozsonyi T; Fehér J; Jakab L
    Allergol Immunopathol (Madr); 1981; 9(1):37-44. PubMed ID: 6973266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of systemic lupus erythematosus (SLE) with the T-cell immunostimulant drug levamisole: A case report.
    Gordon BL; Keenan JP
    Ann Allergy; 1975 Dec; 35(6):343-55. PubMed ID: 1081857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship.
    Wouters CH; Diegenant C; Ceuppens JL; Degreef H; Stevens EA
    Br J Dermatol; 2004 Apr; 150(4):693-700. PubMed ID: 15099365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of Levamisole on peripheral blood lymphocyte subpopulations in patients with rheumatoid arthritis and ankylosing spondylitis.
    Rosenthal M; Trabert U; Müller W
    Clin Exp Immunol; 1976 Sep; 25(3):493-6. PubMed ID: 1085681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of plasmapheresis on cellular immunity abnormalities in patients with systemic lupus erythematosus.
    Bonomini V; Vangelista A; Frascà GM; Nanni-Costa A; Borgnino LC
    Clin Nephrol; 1984 Sep; 22(3):121-6. PubMed ID: 6237815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum factors inhibiting cellular immunity in systemic lupus erythematosus].
    Lavalle C; Alcocer J; Gudiño J; Fraga A
    Prensa Med Mex; 1978; 43(1-2):16-20. PubMed ID: 309127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of lymphocyte subpopulations in normal humans and patients with systemic lupus erythematosus by fractionation of peripheral blood lymphocytes on a discontinuous Ficoll gradient.
    Glinski W; Gershwin ME; Budman DR; Steinberg AD
    Clin Exp Immunol; 1976 Nov; 26(2):228-38. PubMed ID: 1086753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis of T-immunodeficiencies in lupus erythematosus and patient treatment with levamisole].
    Shaposhnikov OK; Gorbunov VF
    Vestn Dermatol Venerol; 1979 Mar; (3):3-6. PubMed ID: 311566
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of levamisole (Decaris) on various immunologic parameters in patients with systemic lupus erythematosus].
    Gandzha IM; Sakharchuk VM; Lysenko GI
    Ter Arkh; 1981; 53(7):121-4. PubMed ID: 6457406
    [No Abstract]   [Full Text] [Related]  

  • 13. Peripheral blood lymphocyte cell surface markers during the course of systemic lupus erythematosus.
    Messner RP; Lindström FD; Williams RC
    J Clin Invest; 1973 Dec; 52(12):3046-56. PubMed ID: 4584345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of levamisole on the activity of the blood T-lymphocytes and of factors they produce in patients with laryngeal cancer].
    Volosevich LI; Lukach EV; Krivokhatskaia LD
    Eksp Onkol; 1988; 10(3):54-7. PubMed ID: 2970382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levamisole in the treatment of Hodgkin's disease.
    Berényi E; Kávai M; Szabolcsi M; Szegedi G
    Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning of T-lymphocytes in systemic lupus erythematosus.
    Whittingham S; Rodger B; Matthews JV; Mackay IR
    Clin Exp Immunol; 1978 Oct; 34(1):63-8. PubMed ID: 312168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular immune reactivity in patients with rheumatoid arthritis and effects of levamisole.
    Basch CM; Spitler LE; Engleman EG; Engleman EP
    J Rheumatol; 1977; 4(4):377-88. PubMed ID: 604477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity.
    Robak E; Niewiadomska H; Robak T; Bartkowiak J; Błoński JZ; Woźniacka A; Pomorski L; Sysa-Jedrezejowska A
    Mediators Inflamm; 2001 Aug; 10(4):179-89. PubMed ID: 11577994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
    Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
    Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.